Research & Literature

Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.

Strati P, Shanafelt TD

Blood 2015; (126(4)):454-62 doi:10.1182/blood-2015-02-585059.

Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.

Visentin A, Facco M, Frezzato F, et al.

Clinical lymphoma, myeloma & leukemia 2015; (15(10)):612-20.e1-5.

PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).

Okkenhaug K, Burger JA

Current topics in microbiology and immunology 2016; (393()):123-142 doi:10.1007/82_2015_484.

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience.

Van Dyke DL, Werner L, Rassenti LZ, et al.

British journal of haematology 2016; (173(1)):105-13 doi:10.1111/bjh.13933.

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Pospisilova S, Sutton LA, Malcikova J, et al.

Haematologica 2016; (101(3)):263-5 doi:10.3324/haematol.2015.139246.

Chronic lymphocytic leukaemia.

Scarfò L, Ferreri AJ, Ghia P

Critical reviews in oncology/hematology 2016; (104()):169-82.

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

Al-Sawaf O, Fischer K, Herling CD, et al.

European journal of haematology 2017; (98(3)):254-262 doi:10.1111/ejh.12825.

Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.

Rodrigues CA, Gonçalves MV, Ikoma MR, et al.

Revista brasileira de hematologia e hemoterapia 2016; (38(4)):346-357 doi:10.1016/j.bjhh.2016.07.004.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

Wierda WG, Zelenetz AD, Gordon LI, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(3)):293-311 doi:10.6004/jnccn.2017.0030.

Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia.

Rampazzo E, Bojnik E, Trentin L, et al.

Haematologica 2017; (102(7)):e253-e256 doi:10.3324/haematol.2016.157669.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Turtle CJ, Hay KA, Hanafi LA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(26)):3010-3020 doi:10.1200/JCO.2017.72.8519.

Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.

Hallek M

American journal of hematology 2017; (92(9)):946-965 doi:10.1002/ajh.24826.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

Rawstron AC, Kreuzer KA, Soosapilla A, et al.

Cytometry. Part B, Clinical cytometry 2018; (94(1)):121-128 doi:10.1002/cyto.b.21595.

Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.

Yi S, Li Z, Zou D, et al.

Oncotarget 2018; (9(3)):3353-3364 doi:10.18632/oncotarget.23261.

Chronic lymphocytic leukaemia.

Hallek M, Shanafelt TD, Eichhorst B

Lancet (London, England) 2018; (391(10129)):1524-1537 doi:10.1016/S0140-6736(18)30422-7.

Frontline Therapy of CLL: Evolving Treatment Paradigm.

Boddy CS, Ma S

Current hematologic malignancy reports 2018; (13(2)):69-77 doi:10.1007/s11899-018-0438-x.

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Seymour JF, Kipps TJ, Eichhorst B, et al.

The New England journal of medicine 2018; (378(12)):1107-1120 doi:10.1056/NEJMoa1713976.

Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions.

Puente XS, Jares P, Campo E

Blood 2018; (131(21)):2283-2296 doi:10.1182/blood-2017-10-764373.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(19)):1973-1980 doi:10.1200/JCO.2017.76.6840.

Chronic Lymphocytic Leukemia: Diagnosis and Treatment.

Strati P, Jain N, O'Brien S

Mayo Clinic proceedings 2018; (93(5)):651-664 doi:10.1016/j.mayocp.2018.03.002.

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.

Jones J, Mato A, Coutre S, et al.

British journal of haematology 2018; (182(4)):504-512 doi:10.1111/bjh.15421.

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Barr PM, Robak T, Owen C, et al.

Haematologica 2018; (103(9)):1502-1510 doi:10.3324/haematol.2018.192328.

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Campo E, Cymbalista F, Ghia P, et al.

Haematologica 2018; (103(12)):1956-1968 doi:10.3324/haematol.2018.187583.

Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns.

Mosquera Orgueira A, Antelo Rodríguez B, Alonso Vence N, et al.

Frontiers in oncology 2019; (9()):79 doi:10.3389/fonc.2019.00079.

SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia.

Choi MY, Wang HY, Kipps TJ

Clinical lymphoma, myeloma & leukemia 2019; (19(6)):321-325 doi:10.1016/j.clml.2019.05.013.

Chronic lymphocytic leukaemia: from genetics to treatment.

Bosch F, Dalla-Favera R

Nature reviews. Clinical oncology 2019; (16(11)):684-701 doi:10.1038/s41571-019-0239-8.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, et al.

Blood 2019; (134(8)):688-698 doi:10.1182/blood.2019000490.

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.

Hallek M

American journal of hematology 2019; (94(11)):1266-1287 doi:10.1002/ajh.25595.

Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.

Stühlinger MC, Weltermann A, Staber P, et al.

Wiener klinische Wochenschrift 2020; (132(3-4)):97-109 doi:10.1007/s00508-019-1534-1.

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, et al.

American journal of hematology 2019; (94(12)):1353-1363 doi:10.1002/ajh.25638.

Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia.

Sorigue M, Magnano L, Miljkovic MD, et al.

Cytometry. Part B, Clinical cytometry 2020; (98(5)):441-448 doi:10.1002/cyto.b.21849.

The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?

Jain N, OʼBrien S

Cancer journal (Sudbury, Mass.) 2019; (25(6)):374-377 doi:10.1097/PPO.0000000000000417.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.

Wierda WG, Byrd JC, Abramson JS, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(2)):185-217.

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.

Herling CD, Cymbalista F, Groß-Ophoff-Müller C, et al.

Leukemia 2020; (34(8)):2038-2050 doi:10.1038/s41375-020-0747-7.

Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Mantle Cell Lymphoma; Small Cell Variant: A Real Diagnostic Challenge. Case Presentation and Review of Literature.

Ibrahim F, Al Sabbagh A, Amer A, et al.

The American journal of case reports 2020; (21()):e921131 doi:10.12659/AJCR.921131.

Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions.

Arruga F, Gyau BB, Iannello A, et al.

International journal of molecular sciences 2020; (21(5)) doi:10.3390/ijms21051825.

Current Perspectives on Therapy for Chronic Lymphocytic Leukemia.

Awan FT, Al-Sawaf O, Fischer K, Woyach JA

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2020; (40()):1-10 doi:10.1200/EDBK_279099.

Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.

Puła B, Długosz-Danecka M, Salomon-Perzyński A, et al.

Advances in medical sciences 2020; (65(2)):371-377 doi:10.1016/j.advms.2020.06.002.

BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells.

Talbot H, Saada S, Barthout E, et al.

Scientific reports 2020; (10(1)):12572 doi:10.1038/s41598-020-69307-1.

Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience.

Eek D, Blowfield M, Krogh C, et al.

The patient 2021; (14(1)):75-87 doi:10.1007/s40271-020-00440-9.

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

Al-Sawaf O, Zhang C, Tandon M, et al.

The Lancet. Oncology 2020; (21(9)):1188-1200 doi:10.1016/S1470-2045(20)30443-5.

The contribution of CD200 to the diagnostic accuracy of Matutes score in the diagnosis of chronic lymphocytic leukemia in limited resources laboratories.

Jalal SD

PloS one 2021; (16(2)):e0247491 doi:10.1371/journal.pone.0247491.

Health state utility and quality of life measures in patients with chronic myeloid leukemia in France.

S F, P CM, A GB, et al.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2021; (30(7)):2021-2032 doi:10.1007/s11136-021-02794-5.

Clinical outcome and prognostic factors in dogs with B-cell chronic lymphocytic leukemia: A retrospective study.

Rout ED, Labadie JD, Yoshimoto JA, et al.

Journal of veterinary internal medicine 2021; (35(4)):1918-1928 doi:10.1111/jvim.16160.

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

Smolej L, Vodárek P, Écsiová D, Šimkovič M

Cancers 2021; (13(13)) doi:10.3390/cancers13133134.

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

Byrd JC, Hillmen P, Ghia P, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(31)):3441-3452 doi:10.1200/JCO.21.01210.

Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia.

Vitale C, Boccellato E, Comba L, et al.

Cancers 2021; (13(15)) doi:10.3390/cancers13153856.

Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study.

Trevino KM, Martin P, Chen Z, Leonard JP

Clinical lymphoma, myeloma & leukemia 2022; (22(2)):82-88 doi:10.1016/j.clml.2021.08.001.

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.

Hallek M, Al-Sawaf O

American journal of hematology 2021; (96(12)):1679-1705 doi:10.1002/ajh.26367.

Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.

Morawska M

European journal of haematology 2022; (108(2)):91-98 doi:10.1111/ejh.13722.

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.

Tam CS, Dimopoulos M, Garcia-Sanz R, et al.

Blood advances 2022; (6(4)):1296-1308 doi:10.1182/bloodadvances.2021005621.

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.

Langerbeins P, Zhang C, Robrecht S, et al.

Blood 2022; (139(2)):177-187 doi:10.1182/blood.2021010845.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Secondary Acquisition of t(11;14)(q13;q32)/CCND1-IGH: A Rare Variant Of Richter Transformation to Mantle Cell Lymphoma.

Zhao Y, McCracken J, Rehder C, Wang E

Clinical lymphoma, myeloma & leukemia 2022; (22(5)):e310-e313 doi:10.1016/j.clml.2021.10.017.

Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia.

Lyski ZL, Kim MS, Xthona Lee D, et al.

Blood advances 2022; (6(4)):1207-1211 doi:10.1182/bloodadvances.2021006633.

Intestinal Infiltration of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Found on Screening Colonoscopy.

Aje KT, Abegunde AT, Mirza K

Cureus 2022; (14(1)):e21037 doi:10.7759/cureus.21037.

Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.

Wiedmeier-Nutor J, Leis J

Current treatment options in oncology 2022; (23(6)):904-919 doi:10.1007/s11864-022-00953-5.

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.

Wierda WG, Brown J, Abramson JS, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(6)):622-634.

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.

St-Pierre F, Ma S

Blood and lymphatic cancer : targets and therapy 2022; (12()):81-98 doi:10.2147/BLCTT.S326627.

Molecular map of chronic lymphocytic leukemia and its impact on outcome.

Knisbacher BA, Lin Z, Hahn CK, et al.

Nature genetics 2022; (54(11)):1664-1674 doi:10.1038/s41588-022-01140-w.

Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma.

Dong Q, Wang Y, Xiu Y, et al.

British journal of haematology 2023; (200(5)):660-664 doi:10.1111/bjh.18565.

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.

Hillmen P, Eichhorst B, Brown JR, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(5)):1035-1045 doi:10.1200/JCO.22.00510.

Patient perspectives of 'Watch and Wait' for chronic haematological cancers: Findings from a qualitative study.

McCaughan D, Roman E, Sheridan R, et al.

European journal of oncology nursing : the official journal of European Oncology Nursing Society 2023; (65()):102349 doi:10.1016/j.ejon.2023.102349.

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

Mato AR, Woyach JA, Brown JR, et al.

The New England journal of medicine 2023; (389(1)):33-44 doi:10.1056/NEJMoa2300696.

Atypical Chronic Lymphocytic Leukemia-The Current Status.

Robak T, Krawczyńska A, Cebula-Obrzut B, et al.

Cancers 2023; (15(18)) doi:10.3390/cancers15184427.

Frequency of <em>TP53</em> Mutation in B-Cell Chronic Lymphocytic Leukaemia and its Association with Lymphocyte Doubling Time.

Ali SM, Irfan SM, Raza N

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2023; (33(11)):1249-1253 doi:10.29271/jcpsp.2023.11.1249.

Mice Overexpressing Wild-Type RRAS2 Are a Novel Model for Preclinical Testing of Anti-Chronic Lymphocytic Leukemia Therapies.

Hortal AM, Villanueva A, Arellano I, et al.

Cancers 2023; (15(24)) doi:10.3390/cancers15245817.

Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment.

Zhang X, Wang H, Zhang Y, Wang X

Clinical and experimental medicine 2024; (24(1)):54 doi:10.1007/s10238-023-01268-x.

PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL.

Farhat M, Croft W, Parry HM, et al.

Leukemia 2024; (38(8)):1813-1817 doi:10.1038/s41375-024-02271-1.

Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.

Nunes RAB, Avezum Á, de Oliveira Marques M, et al.

Annals of hematology 2024; (103(11)):4613-4620 doi:10.1007/s00277-024-05921-7.

"Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): unraveling the biological gray zone of CLL/SLL in the era of novel therapies.

Vadasz B, Zak T, Aldinger J, et al.

Virchows Archiv : an international journal of pathology 2025; (486(4)):739-750 doi:10.1007/s00428-024-03920-7.

Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.

Hampel PJ, Rabe KG, Wang Y, et al.

Leukemia 2025; (39(2)):503-507 doi:10.1038/s41375-024-02492-4.

Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.

Molica S, Allsup D

Cancers 2025; (17(1)) doi:10.3390/cancers17010119.

Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia.

Molica S

Expert review of hematology 2025; (18(3)):195-200 doi:10.1080/17474086.2025.2469719.

Tonic signaling of the B-cell antigen-specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages.

Díez P, Juanes-Velasco P, García-Vaquero ML, et al.

Molecular oncology 2025; (19(12)):3706-3728 doi:10.1002/1878-0261.70032.

Effects of a strength physical exercise program in chronic lymphocytic leukemia patients on quality of life, mental health, and frailty: a randomized controlled trial study protocol.

Sánchez-González JL, Fernández-Rodríguez EJ, Méndez-Sánchez R, et al.

Frontiers in sports and active living 2025; (7()):1534861 doi:10.3389/fspor.2025.1534861.

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.

Kittai AS, Marchetti M, Al-Sawaf O, et al.

Blood 2025; (146(3)):291-303 doi:10.1182/blood.2024028064.

Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience.

Ghia P, Bajwa N, Corry AJ, et al.

HemaSphere 2025; (9(4)):e70130 doi:10.1002/hem3.70130.

When and How Long to Treat Chronic Lymphocytic Leukemia?

Niemann CU, Varghese A, Munir T, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2025; (45(3)):e473656 doi:10.1200/EDBK-25-473656.

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Munir T, Martinez-Calle N, Xu S, et al.

Oncology and therapy 2025; (13(4)):1055-1070 doi:10.1007/s40487-025-00380-0.

The tumor microenvironment in leukemia: molecular pathways of immune evasion.

Zhu Y, Liu J, Qiu F, et al.

Frontiers in immunology 2026; (17()):1743920 doi:10.3389/fimmu.2026.1743920.